Acurx Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$8.1M | -$14.1M | — | — | — |
| Operating expenses | $8.1M | $14.1M | $14.6M | $12.1M | $12.8M |
| Cash from operations | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
Shares outstanding 4.3M · Free float 37.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.